PLX / Protalix BioTherapeutics Stock: FDA Approval For Elfabrio To Drive Profitability

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , July 31, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE Amer more_horizontal

Protalix received FDA and EU approval for Elfabrio. This puts the company on track for profitability as early as 2023. With a reasonable valuation and more_horizontal

Penny stocks to watch this week. The post Best Penny Stocks To Buy Now: 3 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News more_horizontal

Protalix and Chiesi received a CHMP nod for PRX-102 (pegunigalsidase alfa). There is also an FDA PDUFA date of May 9, 2023. more_horizontal

Shares of plant-derived enzyme therapy concern Protalix BioTherapeutics, Inc. have rallied after its Fabry disease asset PLX-102 received a PDUFA date more_horizontal

Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q3 2022 Results Conference Call November 14, 2022 8:30 AM ET Company Participants Chuck Padala - LifeSci Ad more_horizontal

Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel , Nov. 7, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE Ameri more_horizontal

Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., have announced topline data from more_horizontal